NCT06445517

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ISM8207 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Lymphoid Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: InSilico Medicine Hong Kong Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma

Conditions

• Advanced Solid Tumors
• Relapsed/Refractory B-cell Lymphoma

Interventions

Type	Name	Description
DRUG	ISM8207	Pharmaceutical formulation: Capsules Mode of Administration: Oral

Timeline

• Start date: 2024-04-25
• Primary completion: 2026-11-30
• Completion: 2027-02-28
• First posted: 2024-06-06
• Last updated: 2024-06-07

Locations

2 sites across 1 country: China